News - Powered by Yahoo NewsEquity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indication
CEO of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PLTR) tells shareholders that his firm`s PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications ...
Wed, 23 May 2012 06:14:03 -0700 -
Pluristem's CEO Letter to Shareholder
HAIFA, Israel -- Pluristem Therapeutics, Inc. today announces the below CEO letter to shareholders:
Wed, 23 May 2012 04:00:00 -0700 -
Researchers Present Data Highlighting Potential of Peregrine's PS-Targeting Antibodies to Treat Ocular Herpes ..
TUSTIN, CA-- - Peregrine Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, ...
Thu, 10 May 2012 05:30:00 -0700 -
Over 90 Percent of Surveyed Hematologist-Oncologists in the U.S. are Aware that Takeda/Millennium?s Subcutaneous ..
BioTrends Research Group, one of the world?s leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the most recent TreatmentTrends®: Multiple Myeloma report, in which 104 U.S.-based hematologist-oncologists were surveyed about their current and expected treatment patterns in one of the largest hematological malignancy indications.
Tue, 22 May 2012 05:00:00 -0700 -
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent ..
NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market ...
Wed, 23 May 2012 02:45:00 -0700 -
Phytochem International introduces new 15% and 25% oleuropein olive leaf extract
The new products - olive leaf extracts standardized to 15% or 25% oleuropein - enable buyers to include efficacious doses and meet marketers? price points, said the firm, which also sells a more expensive 40% oleuropein product.
Fri, 04 May 2012 08:06:52 -0700 -
Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain ..
NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids ...
Wed, 23 May 2012 04:24:00 -0700 -
MYOS Signs Distribution Deal, Sees Year One Sales Exceeding $5 Millio
CEDAR KNOLLS, NJ-- - MYOS Corporation , a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced the signing of a distribution ...
Tue, 22 May 2012 05:29:00 -0700 -
Intact Vascular, LLC Hires Scott Kraus as Vice President of Sales and Marketin
Intact Vascular, LLC, today announced the appointment of Scott Kraus to the position of Vice President of Sales and Marketing. He will report directly to Carol Burns, President and
Tue, 22 May 2012 08:22:00 -0700 -
Fake drugs threaten gains made in war on malari
LONDON (Reuters) - Low-quality and fake anti-malarial drugs flooding into markets in Asia and Africa are driving drug resistance and threatening gains made in the fight against the disease in the past decade, according to a study by global health experts. The study found around 36 percent of anti-malarial drugs analysed in southeast Asia were fake, while a third of samples in sub-Saharan Africa ...
Mon, 21 May 2012 23:07:43 -0700 -